Each gram of Hytone® (hydrocortisone) Cream 2½% contains 25 mg of hydrocortisone in a water-washable base of purified water, propylene glycol, glyceryl monostearate SE, cholesterol and related sterols, isopropyl myristate, polysorbate 60, cetyl alcohol, sorbitan monostearate, polyoxyl 40 stearate and sorbic acid. Each mL of Hytone (hydrocortisone) Lotion 2½% contains 25 mg of hydrocortisone in a vehicle consisting of carbomer 940, propylene glycol, polysorbate 40, propylene glycol stearate, cholesterol and related sterols, isopropyl myristate, sorbitan palmitate, cetyl alcohol, triethanolamine, sorbic acid, simethicone, and purified water.
Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Media Articles Related to Hytone ( Topical)
Mass. General study points to the first topical treatment for common benign skin lesions
Source: Dermatology News From Medical News Today [2016.02.01]
An investigation into the molecular mechanisms responsible for the most common type of benign skin lesion may lead to the first nonsurgical treatment for the growths called seborrheic keratoses...
FDA Approves 1st Topical Gel to Ease Redness of Rosacea
Source: MedicineNet brimonidine Specialty [2013.08.28]
Title: FDA Approves 1st Topical Gel to Ease Redness of Rosacea
Category: Health News
Created: 8/27/2013 12:35:00 PM
Last Editorial Review: 8/28/2013 12:00:00 AM
Burn Risk Seen with Topical Pain Relievers
Source: MedPage Today Product Alert [2012.09.13]
WASHINGTON -- The FDA warned Thursday of the risks of rare but serious chemical burns with certain over-the-counter topical pain relievers, including Bengay, Capzasin, Flexall, Icy Hot, and Mentholatum.
PodMed: A Medical News Roundup From Johns Hopkins (with audio)
Source: MedPageToday.com - medical news plus CME for physicians [2016.02.06]
(MedPage Today) -- This week's topics include a Zika virus update, choice of topical agents before C-section, surgery resident hours, and rivaroxaban trial questions
Published Studies Related to Hytone ( Topical)
Efficacy of Benzocaine 20% Topical Anesthetic Compared to Placebo Prior to
Administration of Local Anesthesia in the Oral Cavity: A Randomized Controlled
The aim of the present study was to compare the effects of a topical anesthetic
to a placebo on pain perception during administration of local anesthesia in 2
regions of the oral cavity. A split-mouth, double-blind, randomized clinical
trial design was used...
Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a
pilot study. 
treatment of PPE... CONCLUSIONS: In this limited, single-center study, topical cream containing 1 %
Topical analgesia treats pain and decreases propofol use during lumbar punctures
in a randomized pediatric leukemia trial. 
CONCLUSIONS: This study demonstrated that the combination of EMLA cream with
Effectiveness of topical curcumin for treatment of mastitis in breastfeeding
women: a randomized, double-blind, placebo-controlled clinical trial. 
inflammation in women suffering from lactational mastitis... CONCLUSION: The results of the current study indicate that topical preparation of
"Coffee plus honey" versus "topical steroid" in the treatment of
chemotherapy-induced oral mucositis: a randomised controlled trial. 
steroid, honey, honey plus coffee) in patients suffering from oral mucositis... CONCLUSION: Oral mucositis can be successfully treated by a combination of honey
Clinical Trials Related to Hytone ( Topical)
The Influence of Different Hydrocortisone Replacement Doses on the Partitioning and Flexibility of Ectopic Lipids in Patients With Corticotropic Hypopituitarism [Recruiting]
This study aims at assessing the effect of today's standard of hydrocortisone dosage versus
previous hydrocortisone dosage on flexibility and partitioning of ectopic lipid depots (IMCL
and IHCL) after a standardised fat load followed by a short-term aerobic exercise in
patients with corticotropic pituitary insufficiency.
Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia [Recruiting]
Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia [Completed]
This study will test a new, extended release form of hydrocortisone called Chronocort in
patients with congenital adrenal hyperplasia (CAH). People with CAH do not make enough of
the adrenal hormones cortisol and aldosterone, and their adrenal glands make too much of the
sex hormone androgen. Medicines called glucocorticoids (hydrocortisone, dexamethasone and
prednisone) are currently used to treat CAH, but finding the best dose of these drugs that
effectively lowers androgens without causing undesirable side effects, such as weight gain
and slow growth rate in children, is often difficult to achieve.
Adolescents and adults with CAH due to 21-hydroxylase deficiency may be eligible for this
study. Children 16 years of age and older are eligible with confirmation by bone age that
they are no longer growing.
Participants undergo the following tests and procedures during two inpatient visits one
month apart at the NIH Clinical Center:
- Medical history and physical examination.
- Medications: Following 7 days of Cortef (standard drug treatment for CAH), patients
begin taking Chronocort on day 3 of hospitalization and continue the tablets once a day
for 1 month.
- Blood tests: A catheter (plastic tube) is inserted in a vein and left in place for
frequent blood draws in order to avoid repeated needlesticks. Blood is drawn for
chemistries, blood count, pregnancy test in women, and for serial tests (up to 26
samples in a 24-hour period) to measure hormone levels.
- 24-hour urine test.
- Height and weight measurements.
Between the two hospitalizations, patients are contacted by NIH weekly to check for possible
side effects from Chronocort. Two weeks after the first visit, patients also will have blood
drawn by their regular doctor or a local clinic. A few days before the second
hospitalization, patients undergo a 20-minute telephone questionnaire about energy level and
About 30 days after discharge from the second hospitalization, patients are followed up with
a telephone call to see how they are doing.
Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency [Completed]
This is a randomised, controlled, open, two-armed, two-period cross-over, multi-centre phase
II/III study to assess the safety, tolerability and pharmacokinetics of once-daily oral
modified-release hydrocortisone in comparison to conventional thrice-daily oral
hydrocortisone tablets in patients with adrenal insufficiency
Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration [Completed]
The current study will test the causal relationship between elevated levels of cortisol and
the serotonin transporter gene (5-HTTLPR) as these factors influence sensitivity to
environmental threat. The investigators predict that carriers of the short allele of the
serotonin transporter gene who have elevated cortisol levels will be most sensitive to
threatening environments, whereas carriers of the long allele who do not have elevated
cortisol (placebo subjects) will be least sensitive.